PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Vaccination – Market size and forecast 2018-2023
• Drug therapy – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Abbott
• GlaxoSmithKline
• Merck
• Novartis
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for the treatment of herpes zoster
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Vaccination – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Vaccination – Year-over-year growth 2019-2023 (%)
Exhibit 22: Drug therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Drug therapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Vendor landscape
Exhibit 38: Landscape disruption
Exhibit 39: Vendors covered
Exhibit 40: Vendor classification
Exhibit 41: Market positioning of vendors
Exhibit 42: Abbott – Vendor overview
Exhibit 43: Abbott – Business segments
Exhibit 44: Abbott – Organizational developments
Exhibit 45: Abbott – Geographic focus
Exhibit 46: Abbott – Segment focus
Exhibit 47: Abbott – Key offerings
Exhibit 48: GlaxoSmithKline – Vendor overview
Exhibit 49: GlaxoSmithKline – Business segments
Exhibit 50: GlaxoSmithKline – Organizational developments
Exhibit 51: GlaxoSmithKline – Geographic focus
Exhibit 52: GlaxoSmithKline – Segment focus
Exhibit 53: GlaxoSmithKline – Key offerings
Exhibit 54: Merck – Vendor overview
Exhibit 55: Merck – Business segments
Exhibit 56: Merck – Organizational developments
Exhibit 57: Merck – Geographic focus
Exhibit 58: Merck – Key offerings
Exhibit 59: Novartis – Vendor overview
Exhibit 60: Novartis – Business segments
Exhibit 61: Novartis – Organizational developments
Exhibit 62: Novartis – Geographic focus
Exhibit 63: Novartis – Segment focus
Exhibit 64: Novartis – Key offerings
【掲載企業】
Abbott、GlaxoSmithKline、Merck、Novartis